Accepted Manuscript

Evidence on botulinum toxin in selected disorders

Simpson, Elina Zakin

PII: S0041-0101(18)30033-3

DOI: 10.1016/j.toxicon.2018.01.019

Reference: TOXCON 5808

To appear in: Toxicon


Received Date: 16 August 2017

Revised Date: 29 November 2017

Accepted Date: 28 January 2018

Please cite this article as: Simpson, , Zakin, E., Evidence on botulinum toxin in selected disorders, *Toxicon* (2018), doi: 10.1016/j.toxicon.2018.01.019.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 EVIDENCE ON BOTULINUM TOXIN IN SELECTED DISORDERS

2

3 Abstract:

4 Botulinum toxin (BoNT) is a neurotoxin produced by the bacteria *Clostridium botulinum* 5 that has become widely used for various neurologic indications. The four toxin formulations 6 currently available for use in the United States (approved by the Food and Drug Administration) 7 are onabotulinumtoxinA (Botox®), abobotulinumtoxinA (Dysport®), incobotulinumtoxinA (Xeomin[®]), and rimabotulinumtoxinB (Myobloc[®]). While the FDA-approved labels indicate that 8 9 potency conversions should not be done, literature supports relative dose equivalents of 10 approximately 1:1:2-4:50-100, respectively. The aim of this paper is to review the evidence on the use of BoNT formulations available in the United States for specific neurologic disorders, 11 including blepharospasm, cervical dystonia (CD), upper and lower extremity spasticity and 12 13 chronic migraine. Data from the updated 2016 American Academy of Neurology (AAN) 14 guidelines are presented and the level of evidence for use of the four available preparations of 15 BoNT are discussed (table 2 in appendix).

16 For the management of blepharospasm, the recommendations are for use of onaBoNT-A and incoBoNT-A injections with level B evidence. For the management of CD, the 17 recommendations are for use of aboBoNT-A and rimaBoNT-B with level A evidence. For the 18 19 management of upper extremity spasticity, the recommendations are for use of aboBoNT-A, 20 incoBoNT-A and onaBoNT-A with level A evidence. For the management of lower extremity 21 spasticity, the recommendations are for use of onaBoNT-A and aboBoNT-A with level A evidence. For the management of chronic migraines, the recommendations are for use of 22 onaBoNT-A to help improve headache-free days, with level A evidence. It is important for the 23 24 clinician to understand that BoNT is for use in symptomatic control for the underlying 25 neurologic disorder and, at present, has not shown a role in disease modification.

26

		/			
27	Key Words: BoNT; blepharospasm;	cervical d	vstonia limh	snasticity	chronic migraine
21	Ref Words. Don't, Diepharospasifi,	cervicar a	ystoma, mno	spasticity,	chi onic ningi anic

28	Ć
29	
30	
31	
32	
33	
34	

دريافت فورى 🛶 متن كامل مقاله

- امکان دانلود نسخه تمام متن مقالات انگلیسی
 امکان دانلود نسخه ترجمه شده مقالات
 پذیرش سفارش ترجمه تخصصی
 امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
 امکان دانلود رایگان ۲ صفحه اول هر مقاله
 امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
 دانلود فوری مقاله پس از پرداخت آنلاین
 پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات
- ISIArticles مرجع مقالات تخصصی ایران